patients with chronic hepatieis B were treated with recombinant interferon α Ⅰb 3 million IU with intramuscular in jecton every other day for five months The control group was treated with recombinant interferon α Ⅱb with same dose wsage and course At the end of treatment, serum HBeAg reansforming negative were 47 0% and 45 0%, respectively, HBV DNA transforming negative were 53 0% and 50 0%, respectively One year after the last administration, HBeAg transforming negative were 37 0% and 36 0% There is no statistical significance between the two groups (P>0 05) This shous that SINOGEN has the same therapeutn efficacy from Intron A but has Iower side effect than Intron A Meanuhile the index of hepatic fibrosis in serum were detected before and after treatment HA were 162 7±68 5 and 97 5±43 3, respectively (P<0 05) Ⅳ c were 79 8±36 7and56 5±24 2, respectively (P<0 05) It indicates that SINOGEN has efficacy of antihepatic fibrosis [WT5”HZ]
DownLoad: